Ogden Christopher sold $5K of CTMX
Ogden Christopher (Chief Financial Officer) sold 1,624 shares of CytomX Therapeutics, Inc. (CTMX) at $3.05 on 2026-06-15.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale of 1,624 shares at $3.05, totaling ~$4,953, with holdings after the sale reported as 295,324 shares.
Market read
Traders may note incremental sentiment from insider selling, but the disclosure lacks a fundamental catalyst and is unlikely to drive sustained repricing.
What to watch
Transaction size is small relative to typical market impact; without accompanying guidance/clinical/regulatory updates, price reaction should be muted.
Background
This is an SEC Form 4 insider transaction disclosure for CytomX Therapeutics, filed via EDGAR.
Ticker impact
CytomX CFO Ogden Christopher sold 1,624 shares in an open-market transaction at $3.05 on 2026-06-15, per Form 4.
Low near-term impact; any reaction likely limited to sentiment/flow rather than a new catalyst.
The filing is a Form 4 insider sale (not a buy), but the disclosed size (~$5k) is small and the article provides no new company-specific operational or financial developments.
Market effects
Minimal; small insider sale does not meaningfully alter biotech/clinical read-through.
None indicated.
None indicated.
Counterpoint
Insider sales can be planned for liquidity/taxes; absence of a stated 10b5-1 plan doesn’t necessarily imply negative outlook.
Key entities
- issuerCytomX Therapeutics, Inc.
Subject of the Form 4 insider transaction; CFO sold shares at $3.05.
- insiderOgden Christopher
CytomX CFO who executed the open-market sale.